


Equilar Atlas SEO | Page Not Available (404)












 
















Log in | Sign up













PAGE NOT AVAILABLE


Please click here to continue.













				Browse individual profiles:
				
					 A
				
					 B
				
					 C
				
					 D
				
					 E
				
					 F
				
					 G
				
					 H
				
					 I
				
					 J
				
					 K
				
					 L
				
					 M
				
					 N
				
					 O
				
					 P
				
					 Q
				
					 R
				
					 S
				
					 T
				
					 U
				
					 V
				
					 W
				
					 X
				
					 Y
				
					 Z



			� 2017 Equilar, Inc.  | 
			About
			 | 
			Terms of Use
			 | 
			Executive Rankings














 


   Avery Catlin | Celldex Therapeutics , Inc. | ZoomInfo.com


CRBP Avery W. Catlin Insider Trades for Corbus Pharmaceuticals Holdings Inc.


































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Corbus Pharmaceuticals Holdings Inc.

                  NASDAQ: CRBP
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Corbus Pharmaceuticals Holdings Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:33 p.m.


CRBP

/quotes/zigman/50318962/composite


$
6.40




Change

-0.0013
-0.02%

Volume
Volume 2,744
Quotes are delayed by 20 min








/quotes/zigman/50318962/composite
Previous close

$
			6.40
		


$
				6.40
			
Change

0.00
0.00%





Day low
Day high
$6.35
$6.60










52 week low
52 week high

            $2.76
        

            $10.78
        


















Insider Activity


Individual




Avery W. Catlin



Mr. Avery W. Catlin is Independent Director at Corbus Pharmaceuticals Holdings, Inc., CFO, Secretary, Treasurer & Senior Vice President at Celldex Therapeutics, Inc. and Chief Financial Officer at CuraGen Corp. He is on the Board of Directors at Corbus Pharmaceuticals Holdings, Inc. 
Mr. Catlin was previously employed as Chief Financial Officer, Secretary & SVP by AVANT Immunotherapeutics, Inc., Chief Financial Officer & VP-Operations by Endogen, Inc., Chief Financial Officer by Repligen Corp., and Chief Financial Officer by MediSense, Inc. 
He received his undergraduate degree from the University of Virginia and an MBA from Babson College. 



Transactions


Date
Shares
Transaction
Value





05/11/2017
5,000


 
Acquisition at $6.15 per share.


30,750


11/22/2016
2,000


 
Acquisition at $7.55 per share.


15,100


08/18/2015
8,212


 
Acquisition at $1.9 per share.


15,602


08/17/2015
1,788


 
Acquisition at $1.9 per share.


3,397


08/17/2015
5,000


 
Acquisition at $1.95 per share.


9,750


08/17/2015
5,000


 
Acquisition at $1.94 per share.


9,700


06/09/2015
20,000


 
Acquisition at $3.1 per share.


62,000





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Mark A. Tepper 
President & Chief Scientific Officer




Dr. Yuval  Cohen 
Chief Executive Officer & Director




Mr. Sean F. Moran 
CFO & Principal Accounting Officer




Dr. Barbara  White 
Chief Medical Officer




Mr. David P. Hochman 
Director




Mr. Alan F. Holmer 
Chairman




Mr. Avery W. Catlin 
Independent Director




Dr. Renu  Gupta 
Independent Director
















Log In




8:06 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pThe dark side of cruises
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:46p5 easily avoidable reasons why millennials can’t have nice things (or save any money)
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:44pHow Elon Musk and shorter commutes could transform people’s lives
4:43pBanks have raised credit-card interest rates — but not savings account rates
4:43pThe most expensive city in the world is NOT New York or San Francisco
4:42p1 in 10 Americans say they will die in debt
4:40pShopping at Costco, and 5 other things that prove rich people are cheap
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































CLDX Avery W. Catlin Insider Trades for Celldex Therapeutics Inc.


































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Celldex Therapeutics Inc.

                  NASDAQ: CLDX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Celldex Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 5:47 p.m.


CLDX

/quotes/zigman/112431/composite


$
2.37




Change

+0.01
+0.42%

Volume
Volume 8,733
Quotes are delayed by 20 min








/quotes/zigman/112431/composite
Previous close

$
			2.38
		


$
				2.36
			
Change

-0.02
-0.84%





Day low
Day high
$2.35
$2.42










52 week low
52 week high

            $2.20
        

            $5.02
        


















Insider Activity


Individual




Avery W. Catlin



Mr. Avery W. Catlin is Independent Director at Corbus Pharmaceuticals Holdings, Inc., CFO, Secretary, Treasurer & Senior Vice President at Celldex Therapeutics, Inc. and Chief Financial Officer at CuraGen Corp. He is on the Board of Directors at Corbus Pharmaceuticals Holdings, Inc. 
Mr. Catlin was previously employed as Chief Financial Officer, Secretary & SVP by AVANT Immunotherapeutics, Inc., Chief Financial Officer & VP-Operations by Endogen, Inc., Chief Financial Officer by Repligen Corp., and Chief Financial Officer by MediSense, Inc. 
He received his undergraduate degree from the University of Virginia and an MBA from Babson College. 



Transactions


Date
Shares
Transaction
Value





09/02/2016
10,000


 
Derivative/Non-derivative trans. at $2.8 per share.


28,000


06/03/2016
2,847


 
Derivative/Non-derivative trans. at $4.5 per share.


12,811


06/03/2016
20,000


 
Derivative/Non-derivative trans. at $2.8 per share.


56,000


03/09/2016
15,000


 
Derivative/Non-derivative trans. at $2.8 per share.


42,000


11/23/2015
25,000


 
Disposition at $18 per share.


450,000


11/23/2015
25,000


 
Derivative/Non-derivative trans. at $8.52 per share.


213,000


09/11/2015
10,000


 
Derivative/Non-derivative trans. at $4.5 per share.


45,000


06/15/2015
25,000


 
Disposition at $24.59 per share.


614,750


06/15/2015
25,000


 
Derivative/Non-derivative trans. at $8.52 per share.


213,000


09/08/2014
10,000


 
Derivative/Non-derivative trans. at $4.5 per share.


45,000


12/06/2013
183,333


 
Disposition at $24.5 per share.


4,491,659


12/06/2013
183,333


 
Derivative/Non-derivative trans. at $8.16 per share.


1,495,997


07/01/2013
500


 



2,975





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Anthony S. Marucci 
President, Chief Executive Officer & Director




Mr. Sam  Martin 
Chief Financial Officer & Senior Vice President




Dr. Tibor  Keler 
Chief Scientific Officer & Executive VP




Dr. Thomas Andrew Davis 
Chief Medical Officer & Executive Vice President




Ms. Sarah Boylan Cavanaugh 
Senior VP-Corporate Affairs & Administration




Ms. Elizabeth  Crowley 
Chief Product Development Officer & SVP




Dr. Ronald A. Pepin 
Chief Business Officer & Senior Vice President




Dr. Richard  Wright 
Chief Commercial Officer & Senior Vice President




Mr. Keith L. Brownlie 
Director




Mr. James J. Marino 
Director




Dr. Gerald  McMahon 
Director




Dr. Theresa M. LaVallee 
Senior VP-Regulatory & Precision Medicine




Mr. Larry  Ellberger 
Chairman




Ms. Karen Lipton Shoos 
Independent Director




Mr. George O. Elston 
Independent Director




Mr. Harry H. Penner 
Independent Director




Mr. Herbert J. Conrad 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:06 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pThe dark side of cruises
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:46p5 easily avoidable reasons why millennials can’t have nice things (or save any money)
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:44pHow Elon Musk and shorter commutes could transform people’s lives
4:43pBanks have raised credit-card interest rates — but not savings account rates
4:43pThe most expensive city in the world is NOT New York or San Francisco
4:42p1 in 10 Americans say they will die in debt
4:40pShopping at Costco, and 5 other things that prove rich people are cheap
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          









Avery W Catlin











































Home
Search
Sign-In/Up
Contracts
Dictionary
Clauses
Companies
People

About
FAQ
Blog








Follow Avery W Catlin contracts
Click to sign-up for email updates.

      Loading...
    





Home



Sample Contracts



By Executive


Avery W Catlin


Avery W Catlin

SEC Documents
Filings
Personal financials
Insider transactions
Previous Companies

Celldex Therapeutics
(NASDAQ:CLDX)


Sample Contracts with Avery W Catlin




Second Amendment to Lease
(February 23rd, 2016)
This Second Amendment to Lease (this Amendment) is dated as of August 1, 2015, by and between DIV NEEDHAM 115 LLC, a Massachusetts limited liability company (successor-in-interest to Fourth Avenue Ventures Limited Partnership), as landlord (Landlord), and CELLDEX THERAPEUTICS, INC., a Delaware corporation (successor-by name-change to T Cell Sciences, Inc. and Avant Immunotherapeutics, Inc.), as tenant (Tenant), with respect to that certain Lease dated as of May 1, 1996 (the 1996 Lease), as amended by that certain First Amendment to Lease dated as of November 29, 2005 (the First Amendment; the 1996 Lease as amended by the First Amendment is referred to herein as the Original Lease, and the Original Lease as amended hereby is referred to herein as the Lease), by and between Landlord and Tenant, regarding certain premises (the Existing Premises) constituting approximately 35,189 rentable square feet on the first (1st) floor of the building located at 115-119 Fourth Avenue, Needham, Massac




Eighth Amendment to Lease
(February 23rd, 2016)
This EIGHTH AMENDMENT TO LEASE (this Amendment) is made as of the 1st day of November, 2015, (the Effective Date) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (Landlord) and CELLDEX THERAPEUTICS, INC. (formerly AVANT Immunotherapeutics, Inc.), a Delaware corporation, with an address of 119 Fourth Avenue, Needham, Massachusetts (Tenant).




Employment Agreement
(December 21st, 2012)
This EMPLOYMENT AGREEMENT (the Agreement) is entered into this 1st day of January, 2013 (the Effective Date), between Avery W. Catlin (the Executive) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the Company) (collectively, the Executive and the Company shall be referred to as the Parties).  In consideration of the mutual promises and agreements contained herein, the Parties agree as follows:




Celldex Therapeutics, Inc. Controlled Equity Offeringsm Amendment No. 1 to
Sales Agreement
(September 24th, 2012)





AMENDMENT TO CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as
Amended and Restated Effective as of February 24, 2010 Dated: April 17, 2012
(June 14th, 2012)
This Agreement amends the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, as previously amended and restated effective as of February 24, 2010 (the Plan). All capitalized terms not defined herein shall have the meanings set forth in the Plan.




Amendment to Security Agreement
(December 23rd, 2010)
This Amendment to Security Agreement is made as of January 1, 2009, by and between Celldex Therapeutics, Inc. successor in interest to Avant Immunotherapeutics, Inc. (Borrower) and MASSACHUSETTS DEVELOPMENT FINANCE AGENCY, a body politic and corporate created under Massachusetts General Laws Chapter 23G (Lender).




Amendment to Loan Documents
(December 23rd, 2010)
This Amendment to Loan Documents is made as of January 1, 2009, by and between Celldex Therapeutics, Inc. successor in interest to Avant Immunotherapeutics, Inc. (Borrower) and MASSACHUSETTS DEVELOPMENT FINANCE AGENCY, a body politic and corporate created under Massachusetts General Laws Chapter 23G (Lender).




Allonge to Promissory Note
(December 23rd, 2010)
This Allonge to Promissory Note is made as of January 1, 2009, by and between Celldex Therapeutics, Inc., successor in interest to Avant Immunotherapeutics, Inc., a Delaware corporation, (Borrower) and MASSACHUSETTS DEVELOPMENT FINANCE AGENCY, a body corporate and politic created under Massachusetts General Laws chapter 23G, (Lender).




Second Amendment to the Shareholder Rights Agreement
(March 7th, 2008)
SECOND AMENDMENT, dated as of March 7, 2008 (this Amendment), to the Shareholder Rights Agreement, dated as of November 5, 2004 (the Rights Agreement), by and between AVANT Immunotherapeutics, Inc., a Delaware corporation (the Company) and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as rights agent (the Rights Agent). Terms used herein but not defined shall have the meaning assigned to them in the Rights Agreement.




Third Amendment to Amended and Restated Employment Agreement
(October 23rd, 2007)
THIS THIRD AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Amendment) by and between AVANT Immunotherapeutics, Inc., a Delaware  corporation (f/k/a T Cell Sciences, Inc., the Company) and Una S. Ryan, Ph.D. (the Executive), is dated as of October 19, 2007.




Third Amendment to Amended and Restated Employment Agreement
(October 23rd, 2007)
THIS THIRD AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Amendment) by and between AVANT Immunotherapeutics, Inc., a Delaware  corporation (f/k/a T Cell Sciences, Inc., the Company) and Una S. Ryan, Ph.D. (the Executive), is dated as of October 19, 2007.




First Amendment to the Shareholder Rights Agreement
(October 22nd, 2007)
FIRST AMENDMENT, dated as of October 19, 2007 (this Amendment), to the Shareholder Rights Agreement, dated as of November 5, 2004 (the Rights Agreement), by and between AVANT Immunotherapeutics, Inc., a Delaware corporation (the Company) and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as rights agent (the Rights Agent). Terms used herein but not defined shall have the meaning assigned to them in the Rights Agreement.




Avant Immunotherapeutics, Inc. And Equiserve Trust Company, N.A. As Rights
Agent Shareholder Rights Agreement Dated as of November 5, 2004
(November 8th, 2004)
Agreement, dated as of November 5, 2004, between AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and EquiServe Trust Company, N.A., a national trust company (the "Rights Agent").




LEASE From MASSACHUSETTS DEVELOPMENT FINANCE AGENCY, Landlord to AVANT
IMMUNOTHERAPEUTICS, INC.
(April 30th, 2004)





SECURED PROMISSORY NOTE: EQUIPMENT LOAN SUMMARY OF TERMS AND DEFINITIONS Date
of Note:
(April 30th, 2004)
The term Lender shall include successors and assigns   of Massachusetts Development Finance Agency and any future holder of this   Note, and any participants in this Note.




Confidential Treatment Requested as to Certain Information Contained in This
Exhibit SECURITY AGREEMENT: EQUIPMENT (Dated and Effective as of December 22,
2003)
(April 30th, 2004)
WHEREAS, Massachusetts Development Finance Agency, a body politic and corporate and a public instrumentality under the laws of the Commonwealth of Massachusetts with its principal office at 75 Federal Street, Boston, Massachusetts 02110 (together with its successors and/or assigns, the Lender) has agreed to make a loan to AVANT Immunotherapeutics, Inc., a Delaware corporation with its principal office located at 119 Fourth Avenue, Needham, Massachusetts 02494 (the Debtor), such loan being evidenced by that certain Secured Promissory Note: Equipment Loan made by Debtor as of the date hereof to the order of the Lender (the Note).  This Security Agreement, the Note and any UCC-1 financing statements executed in connection with this Security Agreement, as each may be amended or modified from time to time, are referred to herein, collectively, as the Loan Documents.





Follow Avery W Catlin contracts
Click to sign-up for email updates.

      Loading...
    












×









      Have an account? Sign in here.

Law Insider
Recover your password







No account? Register Now!


No account? Register Now!
Sign in
by using one of this services











or







Forgot your password?


Have an account? Sign in here.
Join Law Insider
for Free
by using one of this services











or







By registering you agree to our
      terms of service.










Contract and Agreement Category List











































Home
Search
Sign-In/Up
Contracts
Dictionary
Clauses
Companies
People

About
FAQ
Blog







Sample Contract Categories 

a

b

c

d

e

f

g

h

i

j

k

l

m

n

o

p

q

r

s

t

u

v

w

x

y

z


abcdefghijklmnopqrstuvwxyz


337k
		Delaware
	

277k
		New York
	

113k
		California
	

70k
		Texas
	

68k
		Agreement
	

62k
		Nevada
	

46k
		Florida
	

44k
		Maryland
	

40k
		Illinois
	

38k
		Employment Agreement
	

38k
		Washington
	

37k
		Amended And Restated
	

36k
		Massachusetts
	

34k
		New Jersey
	

33k
		Pennsylvania
	

28k
		Georgia
	

28k
		Colorado
	

26k
		Ohio
	

25k
		Minnesota
	

25k
		Virginia
	

21k
		North Carolina
	

20k
		Incentive Plan
	

19k
		Credit Agreement
	

19k
		Amendment
	

16k
		Connecticut
	

16k
		Michigan
	

15k
		Indiana
	

14k
		Registration Rights Agreement
	

14k
		Recitals
	

13k
		Tennessee
	

13k
		Arizona
	

13k
		Missouri
	

12k
		Purchase Agreement
	

12k
		Promissory Note
	

12k
		Indenture
	

11k
		Warrant
	

11k
		Louisiana
	

11k
		Kansas
	

11k
		Utah
	

11k
		Wisconsin
	

10k
		Oklahoma
	

9k
		Securities Purchase Agreement
	

9k
		Agreement And Plan Of Merger
	

8k
		Iowa
	

8k
		Supplemental Indenture
	

8k
		Note
	

8k
		Equity Incentive Plan
	

7k
		Kentucky
	

7k
		Stock Purchase Agreement
	

7k
		Alabama
	














×









      Have an account? Sign in here.

Law Insider
Recover your password







No account? Register Now!


No account? Register Now!
Sign in
by using one of this services











or







Forgot your password?


Have an account? Sign in here.
Join Law Insider
for Free
by using one of this services











or







By registering you agree to our
      terms of service.




































Management | About | Celldex Therapeutics























Careers    |    Contact     


About

Overview
Management
Board of Directors
Scientific Advisory Board
Business Development
Careers
															
Overview
Benefits
Current Opportunities


Locations


Pipeline

Overview
Glembatumumab vedotin
Varlilumab
CDX-0158
CDX-3379
CDX-1401
CDX-301
CDX-014


Science

Overview
Publications


Clinical Trials

Overview
Compassionate Use


Investors & Media

Investor Relations
Press Releases
Events & Presentations
Stock Information
                                                        	
Overview
Stock Chart
Historic Stock Lookup
Investment Calculator
IRS Form 8937


Financial & SEC Reports
                                                        
Overview
SEC Filings
Annual Reports
Quarterly Results


Corporate Governance
                                                        
Overview
Management
Board of Directors
Committee Composition


Analyst Coverage
Email Alerts
Contact Us




















Overview
Management
Board of Directors
Scientific Advisory Board
Business Development
Careers
Overview
Benefits
Current Opportunities
Locations


















Management

Anthony S. Marucci
Founder, President, Chief Executive Officer and Director

Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received a B.S. in Accounting from Kean University, an MBA from Columbia University and an Executive Master of Healthcare Leadership (EMHL) from Brown University.




Sarah Cavanaugh
Senior Vice President, Corporate Affairs and Administration

Ms. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. Prior to joining Celldex, she served from 2007 to 2012 as a Vice President at MacDougall Biomedical Communications, a strategic communications and investor relations firm for the life sciences industry, where she developed and implemented programs for more than 20 biopharmaceutical companies and served as the in-house oncology expert. Ms. Cavanaugh has served in a number of leadership positions in the health care and life sciences industry, including Director of Corporate Communications for Point Therapeutics, an oncology-focused biotech company, and Director of Corporate Communications for Fallon Community Health Plan, a leading Massachusetts managed care organization. She began her health care career at the American Cancer Society, holding various positions providing leadership in physician education, corporate communications, government relations and marketing. She completed her tenure there as Division Communications and Marketing Director for the Mid-South Division, where she was responsible for managing the efforts of marketing and communications staff across six states. Throughout her career, Ms. Cavanaugh has played a leadership role in organizational development and employee relations/communication. Ms. Cavanaugh received her B.A. from the University of New Hampshire.




Elizabeth Crowley
Senior Vice President, Chief Product Development Officer

Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of Celldex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.




Thomas Davis, M.D.
Executive Vice President and Chief Medical Officer

Dr. Davis is Executive Vice President and Chief Medical Officer of Celldex. Prior to this appointment in 2014, he was Senior Vice President of Clinical Development and Chief Medical Officer of Celldex. Formerly he was Chief Medical Officer at GenVec and Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies and vaccines at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, M.S. in Physiology and M.D. from Georgetown University, and Oncology training at Stanford University.




Tibor Keler, Ph.D.
Founder, Executive Vice President and Chief Scientific Officer

Dr. Keler is a Founder of Celldex and serves as the Company’s Executive Vice President and Chief Scientific Officer. Prior to this appointment in 2014, he was Senior Vice President of Research and Discovery at Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). Previously, Dr. Keler was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the preclinical development of a number of Medarex clinical product candidates. In addition, Dr. Keler was responsible for the development of Celldex's core technology and related products. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.




Sam Martin
Senior Vice President and Chief Financial Officer

Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.




Ronald A. Pepin, Ph.D.
Senior Vice President and Chief Business Officer

Dr. Pepin joined Celldex in July 2011 as Senior Vice President and Chief Business Officer. He previously served as Vice President at Shire Pharmaceuticals. From 2000 – 2009, as Senior Vice President, Business Development at Medarex, Inc., he was instrumental in establishing more than forty collaborations with global biopharmaceutical companies. Earlier in his career, he served as Executive Director of External Science and Technology at Bristol-Myers Squibb. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from Georgetown University.



Richard Wright, Ph.D.
Senior Vice President and Chief Commercial Officer

Dr. Wright is Senior Vice President and Chief Commercial Officer of Celldex. He joined Celldex in 2012 as Vice President of Commercial Operations. Prior to Celldex, Dr. Wright was Managing Director at Navigant Consulting, where he led a Life Sciences practice focused on commercial strategy for oncology, immunology and rare disease therapies. Previously, Dr. Wright was at Bristol-Myers Squibb, where he held senior leadership roles including Senior Vice President of the U.S. Immunology Business and Vice President and Global Commercial Lead for the Immunology Franchise. At Bristol-Myers Squibb, he was responsible for CTLA4-Ig immunotherapies including the blockbuster drug ORENCIA® and the orphan drug NULOJIX®. In these roles he was charged with setting overall business strategy, commercializing the Company’s broad immunology franchise and managing the U.S. marketing and sales organizations. Dr. Wright began his career at Novartis Pharmaceuticals (Sandoz), where he led research aimed at discovering novel inhibitors of cell migration and metastasis, inhibition of tumor-induced angiogenesis and induction of immune tolerance. At Novartis, he later held several roles in new product commercialization, marketing and salesforce leadership in its Transplant and Immunology Business Unit and was responsible for NEORAL®, SIMULECT®, CERTICAN® and MYFORTIC®. Dr. Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University.



 




 







About us


Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.
 
Our Pipeline 





 











About
Overview
Management
Board of Directors
Scientific Advisory Board
Business Development
Careers
Locations


Pipeline
Overview
Glembatumumab vedotin
Varlilumab
CDX-0158
CDX-3379
CDX-1401
CDX-301
CDX-014


Science
Overview
Publications


Clinical Trials
Overview
Compassionate Use


Investors & Media
Investor Relations
Press Releases
Events & Presentations
Stock Information
Financial & SEC Reports
Corporate Governance
Analyst Coverage
Email Alerts
Contact Us













© 2017 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact











 

Avery W. Catlin's involvement in venture capital (via Celldex Therapeutics Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/192734-w-catlin-averysection=people&subsection=detail&id=192734




			Search deals by company name, industry, location, investors...			
			




SEARCH


AveryW. CatlinGet alertedif Avery W. Catlin gets funded!Avery W. CatlinCelldex Therapeutics Inc - SVP & CFODeals involving Avery W. Catlin$2,000,000 raised with Celldex Therapeutics Inc on October, 2014$171,500,000 raised with Celldex Therapeutics Inc on December, 2013Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Avery W. Catlin on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!